一种新型、IBS特异性IgG ELISA指导的排除饮食在肠易激综合征中的随机假饮食对照试验
研究在8个中心纳入238例IBS患者,随机接受实验性抗体指导饮食或假饮食8周,改良意向性分析纳入223例。实验组达到主要终点(腹痛强度下降≥30%持续至少2周)的比例显著高于假饮食组(59.6% vs 42.1%,P=0.02)。亚组分析提示便秘型和混合型IBS获益更明显,需更大规模研究验证。
要点
- IgG指导的排除饮食组达到主要终点的比例显著高于假饮食组(59.6% vs 42.1%,P=0.02)。
- 便秘型IBS亚组实验组67.1% vs 假组35.8%,混合型IBS亚组66% vs 29.5%达到主要终点。
- 作者认为需更大规模研究验证这些观察结果。
核心结论
- IgG指导的排除饮食组达到主要终点的可能性高于假排除饮食组。
- 亚组分析提示便秘型IBS和混合型IBS受试者获益更明显。
- 作者认为需更大规模研究验证这些观察结果。
研究设计与样本
- 随机、双盲、假饮食对照试验,在8个中心纳入IBS受试者。
- 受试者在18种食物IgG检测中至少1种阳性,且2周导入期平均每日腹痛强度评分在11.0分制中为3.0至7.5分。
- 受试者随机接受实验性抗体指导饮食或假饮食8周。
- 238例随机受试者中223例纳入改良意向性治疗分析。
主要发现
- 实验饮食组达到主要终点(治疗期最后4周中至少2周腹痛强度下降≥30%)的比例为59.6%,假饮食组为42.1%(P=0.02)。
- 便秘型IBS亚组实验饮食组67.1% vs 假饮食组35.8%达到主要终点。
- 混合型IBS亚组实验饮食组66% vs 假饮食组29.5%达到主要终点。
局限性
- 作者认为需更大规模研究验证这些观察结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Personalized dietary therapies for irritable bowel syndrome (IBS) are needed and an immunoglobulin (Ig)G-antibody-based elimination diet presents a potential solution. However, existing studies have serious methodological limitations. This study aimed to assess the efficacy of an elimination diet by using a novel IBS-specific IgG assay. METHODS: We conducted a randomized, double-blind, sham-controlled trial enrolling subjects with IBS from 8 centers. Subjects positive for ≥1 food on an 18-food IgG assay and an average daily abdominal pain intensity score between 3.0 and 7.5 on an 11.0-point scale during a 2-week run-in period were randomized to either an experimental antibody-guided diet or sham diet for 8 weeks. The primary outcome was a ≥30% decrease in abdominal pain intensity for ≥2 of the last 4 weeks of the treatment period. RESULTS: Among 238 randomized subjects with IBS, 223 were included in the modified intention-to-treat analysis. A significantly greater proportion of subjects in the experimental diet group met the primary outcome than those in the sham diet group (59.6% vs 42.1%, P = .02). Subgroup analysis revealed that a higher proportion of subjects with constipation-predominant IBS and IBS with mixed bowel habits in the experimental diet group met the primary endpoint vs the sham group (67.1% vs 35.8% and 66% vs 29.5%, respectively). CONCLUSIONS: Subjects on an IgG-guided elimination diet were more likely to achieve the primary endpoint than those on a sham elimination diet. Subgroup analysis suggests a more robust benefit for subjects with constipation-predominant IBS and IBS with mixed bowel habits. This highlights the potential effectiveness of a personalized elimination diet based on a novel IBS-specific IgG assay. A larger study is warranted to validate these observations. (ClinicalTrials.gov, Number NCT03459482.).
引用
- Singh P, Chey WD, Takakura W, et al. A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial. Gastroenterology. 2025. PMID: 39894284. doi:10.1053/j.gastro.2025.01.223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。